Xilio Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Xilio Therapeutics, Inc. filed this Current Report on Form 8-K regarding its 2023 annual meeting of stockholders held on June 8, 2023. The company is a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol XLO.
Financial Metrics and Liquidity
This filing reports no revenue, profit, cash flow, margin, debt, liquidity, or other financial-performance metrics. The filing text does not provide a clear value for these items.
Material Changes Versus the Prior Comparable Period
- Stockholders elected Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D. as Class II directors for three-year terms expiring at the 2026 annual meeting.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Daniel Curran, M.D. | 17,836,373 | 538,925 | 3,812,216 |
| Robert Ross, M.D. | 18,136,312 | 238,986 | 3,812,216 |
| Yuan Xu, Ph.D. | 17,836,313 | 538,985 | 3,812,216 |
| Auditor Ratification | Votes |
|---|---|
| For | 21,955,354 |
| Against | 1,623 |
| Abstaining | 230,537 |
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management commentary, risk updates, contingencies, or unusual financial items. It identifies the company as an emerging growth company.
Key Facts for Investors to Verify
- Confirm the elected directors’ terms and any subsequent changes to board composition.
- Confirm Ernst & Young LLP’s appointment as auditor for the year ending December 31, 2023.
- Review subsequent filings for financial condition, cash runway, clinical-development updates, financing activity, and risk disclosures, none of which are addressed in this 8-K.
- Note that the report was filed regarding the June 8, 2023 meeting and signed on June 13, 2023.